"Orveko has pointed out that A2-73 is currently protected by one patent related to its use as a combination therapy for the treatment of melanoma, but that does not protect 2-73 as a mono-therapy. "
Ok, that jives with what I found out researching the composition of matter patent which expired back in February. I guess that expiry motivated MediSynergics to go after a 2-73 combo. If the results at this conference cause 2-73 to get huge boost in notoriety we may see more companies going after combo drugs with 2-73. I would guess the possibility someone could now take 2-73 and make a combo drug that could exceed the efficacy of 2-73 or 2-73 PLUS adds complexity in dealing with a big pharma potential partner.
News 
Market Data 
Discover 
